Research Article
Expression of uPAR in Urinary Podocytes of Patients with Fabry Disease
Table 2
General characteristics of untreated (no ERT) and ERT-treated Fabry patients.
| | Variables | No ERT (: 23) | ERT (: 21) | value |
| | Age (years) | 19 (11–75) | 35.8 (17–86) | 0.03 | | Gender (males) | 4 (14%) | 13 (59%) | 0.01 | | Hypertension | 1 (4.3%) | 5 (24%) | 0.0001 | | White matter ischaemia | 4 (17%) | 14 (68%) | 0.003 | | Myocardial hypertrophy | 1 (4%) | 5 (24%) | 0.001 | | Time on ERT (months) | 0 | 40 (34–50) | <0.0001 | | eGFR (ml/min/1.73 m2) | 141 (60–165) | 131.5 (62–148) | 0.06 | | UPCR (g/g) | 0.06 (0.02–2.35) | 0.10 (0.02–5.68) | 0.04 | | Urinary uPAR+ podocytes/creatininuria (cells/g) | 40.18 (9.51–284.46) | 20.18 (0–191.26) | 0.009 | | Mutations | D33G, L415P, R227X, A292T, N34D, C801, C326, C647A, C281, G640C | D33G, L415P, R227X, A292T, N34D, D264Y, D155H, L180F | |
|
|
ERT, enzyme replacement therapy. Diagnosed by magnetic resonance imaging; asymptomatic cases, performed for screening purposes.
|
